| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers I > Headlines for Introgen Therapeutics Inc. > News item |
Introgen's INGN 241, in combination with Tarceva, shown to inhibit tumor growth
By Lisa Kerner
Charlotte, N.C., June 6 - Introgen Therapeutics, Inc. said its researchers, along with collaborators at The University of Texas M. D. Anderson Cancer Center, demonstrated that the combination of Introgen's INGN 241 and Tarceva (erlotinib HCl) inhibits activity of the epidermal growth factor receptor (EGFR), a driver for cell growth in cancer, compared to either agent alone.
Preclinical results will be presented at the American Society of Gene Therapy 2006 Annual Meeting, according to a company news release.
INGN 241 is a targeted molecular therapy being evaluated in a phase 2 trial in patients with metastatic melanoma and a phase 3 trial for solid tumors in combination with radiation.
Tarceva, marketed by Genentech, is a small molecule drug approved for the treatment of non-small cell lung cancer and pancreatic cancer.
The preclinical studies evaluated INGN 241 or Tarceva alone and both agents together on human lung and prostate tumor cells. Introgen said that inhibition of EGFR activation was greatest in cells treated with INGN 241 in combination with Tarceva.
"Although several EGFR inhibitors have been approved for use in a variety of cancers, their use as monotherapy has limited impact on clinical response and patient outcome," associate vice president of clinical research and development Sunil Chada said in the release.
"These results suggest that this combination could improve the efficacy of EGFR inhibitors and provides additional evidence of the very broad utility of INGN 241 in a variety of settings and in combination with a growing number of anticancer agents."
Introgen is a biopharmaceutical company located in Baltimore.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.